Activated factor VIII in therapeutic preparations: analysis by ultracentrifugation.
Activation of factor VIII is signaled by an increase in the 1-stage factor VIII activity and release from von Willebrand factor. Ultracentrifugation in 10-40% sucrose gradients was used to identify such activation in therapeutic concentrates. Plasma-derived factor VIII lots were examined and factor VIII sedimenting independently of von Willebrand factor was identified in some of the preparations. In addition there was slower sedimentation of factor VIII by the 1-stage assay than by the chromogenic assay. These results are consistent with a factor VIII cleaved at residue 1689, a site important for von Willebrand binding. This activated form leads to some of the assay discrepancies between the 1-stage assay and the chromogenic or the 2-stage assay. There is more rapid sedimentation of the factor VIII measured by the chromogenic assay than the von Willebrand factor in some manufacturers' samples indicating that the method of fractionation may select a low molecular weight von Willebrand factor which does not bind factor VIII. Routine comparison between the 1-stage and chromogenic assays during fractionation may be able to identify such activated preparations. Other assay discrepancies may be due to structural differences between the standards and the tested product.
Aronson
D L
DL
Division of Hematology, George Washington University Medical Center, Washington, DC 20037, USA.
Chang
P
P
D015944:Factor VIIIa / Q000032:analysis*; D006801:Humans; D012015:Reference Standards; D014461:Ultracentrifugation / Q000379:methods*; D014841:von Willebrand Factor / Q000032:analysis
D014841:von Willebrand Factor; D015944:Factor VIIIa